CY1121261T1 - Ενωση τριαζινης και χρηση εξ αυτης για ιατρικους σκοπους - Google Patents

Ενωση τριαζινης και χρηση εξ αυτης για ιατρικους σκοπους

Info

Publication number
CY1121261T1
CY1121261T1 CY20181101359T CY181101359T CY1121261T1 CY 1121261 T1 CY1121261 T1 CY 1121261T1 CY 20181101359 T CY20181101359 T CY 20181101359T CY 181101359 T CY181101359 T CY 181101359T CY 1121261 T1 CY1121261 T1 CY 1121261T1
Authority
CY
Cyprus
Prior art keywords
triazine
association
medical purposes
compound
mpges
Prior art date
Application number
CY20181101359T
Other languages
English (en)
Inventor
Hironobu Nagamori
Ikuo Mitani
Masaki Yamashita
Takahiro Hotta
Yuichi Nakagawa
Masatoshi Ueda
Original Assignee
Japan Tobacco, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco, Inc. filed Critical Japan Tobacco, Inc.
Publication of CY1121261T1 publication Critical patent/CY1121261T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Παρέχεται μια ένωση έχοντας μια ανασταλτική δραστηριότητα mPGES-1 και χρήσιμη για την προφύλαξη ή αγωγή πόνου, ρευματισμού, οστεοαρθρίτιδας, πυρετού, νόσου του Αλτσχάιμερ, πολλαπλής σκλήρυνσης, αρτηριοσκλήρυνσης, γλαυκώματος, οφθαλμικής υπέρτασης, ισχαιμικής αμφιβληστροειδικής πάθησης, συστημικού σκληροδέματος και καρκίνου συμπεριλαμβάνοντας ορθοκολικό καρκίνο. Μια ένωση που αναπαρίσταται από το χημικό τύπο (I) ή ένα φαρμακευτικώς αποδεκτό άλας εξ αυτής: όπου κάθε ένα σύμβολο είναι ως καθορίζεται στην ΠΡΟΔΙΑΓΡΑΦΗ.
CY20181101359T 2014-02-20 2018-12-19 Ενωση τριαζινης και χρηση εξ αυτης για ιατρικους σκοπους CY1121261T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014031035 2014-02-20
PCT/JP2015/054519 WO2015125842A1 (ja) 2014-02-20 2015-02-19 トリアジン化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
CY1121261T1 true CY1121261T1 (el) 2020-05-29

Family

ID=53878341

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181101359T CY1121261T1 (el) 2014-02-20 2018-12-19 Ενωση τριαζινης και χρηση εξ αυτης για ιατρικους σκοπους

Country Status (31)

Country Link
US (3) US20150266834A1 (el)
EP (2) EP3109240B1 (el)
JP (4) JP6461637B2 (el)
KR (1) KR102360699B1 (el)
CN (1) CN106232585B (el)
AR (1) AR099498A1 (el)
AU (1) AU2015219920B2 (el)
BR (1) BR112016018341B1 (el)
CA (1) CA2936408C (el)
CL (1) CL2016002091A1 (el)
CY (1) CY1121261T1 (el)
DK (1) DK3109240T3 (el)
ES (1) ES2704922T3 (el)
HR (1) HRP20182134T1 (el)
IL (1) IL247319B (el)
LT (1) LT3109240T (el)
MX (1) MX369217B (el)
MY (1) MY183605A (el)
PE (2) PE20161236A1 (el)
PH (1) PH12016501651A1 (el)
PL (1) PL3109240T3 (el)
PT (1) PT3109240T (el)
RS (1) RS58235B1 (el)
RU (1) RU2692789C2 (el)
SA (1) SA516371701B1 (el)
SG (1) SG11201606902QA (el)
SI (1) SI3109240T1 (el)
TR (1) TR201821158T4 (el)
TW (1) TWI651310B (el)
WO (1) WO2015125842A1 (el)
ZA (1) ZA201606449B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
EP3224237A4 (en) * 2014-12-24 2018-02-07 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
JP6478255B2 (ja) * 2015-03-04 2019-03-06 株式会社島津製作所 蛍光誘導体化試薬及びアミン分析方法
BR112018001809A2 (pt) * 2015-08-17 2018-09-18 Japan Tobacco, Inc. composto de hidroxitriazina e uso médico do mesmo
CA3002632C (en) 2015-10-29 2023-08-29 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
GB201603311D0 (en) * 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
WO2018026763A1 (en) * 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3645527A1 (de) * 2017-06-26 2020-05-06 Merck Patent GmbH Verfahren zur herstellung substituierter stickstoffhaltiger heterocyclen
AU2020316364A1 (en) * 2019-07-22 2022-02-24 Angion Biomedica Corp. Ethynylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
US11786538B2 (en) * 2019-12-11 2023-10-17 Somerset Therapeutics, Llc Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties
KR102157466B1 (ko) * 2020-05-19 2020-09-17 동아대학교 산학협력단 헥사하이드로트리아진 유도체를 포함하는 방광암의 예방, 개선 또는 치료용 조성물
JP7277676B2 (ja) 2021-02-02 2023-05-19 あすか製薬株式会社 ピリミジン誘導体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981003020A1 (en) * 1980-04-22 1981-10-29 Commw Scient Ind Res Org Triazine synthesis
DE19543730A1 (de) * 1995-11-23 1997-05-28 Ciba Geigy Ag Bis-Resorcinyl-Triazine
CN1246858A (zh) * 1996-12-05 2000-03-08 安姆根有限公司 取代的嘧啶化合物和它们的应用
TW520362B (en) * 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
US20040082627A1 (en) * 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
EP2138488A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
CN101747282A (zh) * 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
US8952150B2 (en) * 2009-09-23 2015-02-10 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors and uses thereof
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
FR2983859B1 (fr) * 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
CN115536635A (zh) * 2012-01-06 2022-12-30 法国施维雅药厂 治疗活性化合物及其使用方法
TWI568722B (zh) * 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
JP2014031035A (ja) 2012-08-01 2014-02-20 Yamaha Motor Co Ltd 原動機付き鞍乗型車両
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
CN105586773A (zh) * 2014-11-13 2016-05-18 东丽纤维研究所（中国）有限公司 一种拒水抗紫外纺织品及其生产方法和用途

Also Published As

Publication number Publication date
KR102360699B1 (ko) 2022-02-10
TR201821158T4 (tr) 2019-01-21
SG11201606902QA (en) 2016-09-29
EP3109240A4 (en) 2017-07-26
AU2015219920B2 (en) 2018-12-20
MX2016010875A (es) 2016-10-26
NZ721718A (en) 2021-08-27
JP2019065036A (ja) 2019-04-25
CL2016002091A1 (es) 2017-01-20
CN106232585B (zh) 2019-04-02
RU2016137263A3 (el) 2018-10-04
WO2015125842A1 (ja) 2015-08-27
AU2015219920A1 (en) 2016-07-14
RU2016137263A (ru) 2018-03-23
LT3109240T (lt) 2019-01-10
JP6461637B2 (ja) 2019-01-30
US20200087266A1 (en) 2020-03-19
US20230011968A1 (en) 2023-01-12
RS58235B1 (sr) 2019-03-29
JP2021054856A (ja) 2021-04-08
CA2936408C (en) 2022-09-13
PH12016501651B1 (en) 2017-02-06
MX369217B (es) 2019-10-31
TWI651310B (zh) 2019-02-21
RU2692789C2 (ru) 2019-06-27
ES2704922T3 (es) 2019-03-20
ZA201606449B (en) 2017-11-29
EP3109240B1 (en) 2018-10-24
CN106232585A (zh) 2016-12-14
DK3109240T3 (en) 2018-12-17
MY183605A (en) 2021-03-02
PT3109240T (pt) 2019-01-21
BR112016018341A2 (el) 2017-08-08
KR20160113727A (ko) 2016-09-30
EP3109240A1 (en) 2016-12-28
AR099498A1 (es) 2016-07-27
SA516371701B1 (ar) 2019-01-21
PE20161236A1 (es) 2016-11-23
HRP20182134T1 (hr) 2019-02-08
IL247319A0 (en) 2016-09-29
BR112016018341B1 (pt) 2023-02-07
SI3109240T1 (sl) 2019-02-28
PL3109240T3 (pl) 2019-03-29
TW201620881A (zh) 2016-06-16
PE20211548A1 (es) 2021-08-16
EP3456713A1 (en) 2019-03-20
JP2015172039A (ja) 2015-10-01
PH12016501651A1 (en) 2017-02-06
IL247319B (en) 2019-11-28
JP2022120173A (ja) 2022-08-17
US20150266834A1 (en) 2015-09-24
CA2936408A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
CY1121261T1 (el) Ενωση τριαζινης και χρηση εξ αυτης για ιατρικους σκοπους
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1123569T1 (el) Παραγωγα ισοϊνδολινο-1-ονης ως δραστικοτητα θετικου αλλοστερiκου τροποποιητη χολινεργικου μουσκαρινικου μ1 υποδοχεα για τη θεραπεια της νοσου toy alzheimer
CY1125089T1 (el) Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae
AR118371A2 (es) Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina
CY1123353T1 (el) Καινοφανης ενωση συμπυκνωμενης πυριμιδινης ή αλας εξ αυτης
CY1123401T1 (el) Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων
EA201990833A1 (ru) Соединение пиридина
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
CY1124800T1 (el) Παραγωγο πυριδο[3,4-d]πυριμιδινης και φαρμακευτικως αποδεκτο αλας αυτου
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
PH12015502737A1 (en) Novel fused pyrimidine compound or salt thereof
CY1120836T1 (el) Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
CY1119118T1 (el) Θεραπευτικος παραγων για τις διαταραχες της διαθεσης
CY1123842T1 (el) Ετεροαρυλικες ενωσεις για τη θεραπευτικη αντιμετωπιση οφθαλμικων νοσων
PH12017500095A1 (en) Imidazopyridazine compounds
CY1122971T1 (el) Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων
EA201692270A1 (ru) Производные нафтиридиндиона
BR112018001809A2 (pt) composto de hidroxitriazina e uso médico do mesmo
EA201790632A1 (ru) 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса
MY197042A (en) Compounds
PH12016501645A1 (en) Aminopyrazolone derivative